The company is focused on developing and commercializing novel therapies for the most difficult-to-treat cancers, specifically targeting indications for which conventional therapies have failed, with a deep pipeline of differentiated and novel therapeutic candidates targeting critical pathways that cancer cells use to grow. Founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines.
Cyborg Score Rationale
Ibtrozi's commercial launch is robust, with early patient uptake showing strong momentum. The company achieved an impressive revenue growth rate of 1704.68% as of 30 September 2025, signifying a substantial increase in the company's top-line earnings. However, profitability remains challenged as the company is still in early commercialization.
Top Insights
Nuvation Bio is demonstrating strong early commercial success with Ibtrozi, its newly FDA-approved therapy for ROS1-positive non-small cell lung cancer.
The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor.
Over the last 52-week period, shares are up 218.96%, indicating strong investor confidence.
The company generates revenue through out-licensing collaborative agreements with customers located in China and Japan.
Named Competitors
Alunbrig (brigatinib) — ROS1 inhibitor for advanced non-small cell lung cancer
Rozlytrek (entrectinib) — ROS1/TRK inhibitor for advanced non-small cell lung cancer
NUV-1 candidates — Focused on precision oncology targeted therapies
Recent Developments
(February 2026) Q4 2025 earnings announcement scheduled for March 2, 2026 with analyst expectations of -$0.07 EPS
(November 2025) Q3 2025 earnings reported strong commercial progress with Ibtrozi and updated clinical data
(2025) FDA approval of Ibtrozi (taletrectinib) for ROS1+ NSCLC with successful commercial launch
Open the full interactive Nuvation Bio Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.